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Approximately 8–12% of all melanoma cases occurs in patients
with a family history of the disease (Greene and Fraumeni, 1979),
suggesting genetic susceptibility as a predisposing factor to
melanoma. Familial melanoma is considered a genetically hetero-
geneous disease as supported by different lines of investigation
including genetic linkage analyses that have identified at least 2
loci, on chromosomes 9p21 and 1p36, cosegregating with
melanoma susceptibility (Haluska and Hodi, 1998). The CDKN2A
gene, at 9p21, encodes a product, known as p16, that functions as
a negative regulator of the cell cycle progression at the G1–S
checkpoint. It binds specifically and blocks the activity of 2
cyclin-dependent protein kinases, CDK4 and CDK6, which coor-
dinately phosphorylate and functionally inactivate the product of
the RB tumour suppressor gene (Ruas and Peters, 1998). Thus,
changes in the expression of one of these proteins or mutations
that impair their interaction may allow unchecked cell growth,
contributing to cell transformation. While mutations in the
CDKN2A gene normally interfere with binding of p16 to CDK4,
rare mutated CDK4 alleles function as dominant oncogenes as
their encoded proteins escape p16-binding and inhibition thus
retaining the ability to phosphorylate pRB (Zuo et al, 1996). 
A number of molecular studies on melanoma families from
Australia, North America and Europe have been reported and the
presence of germ line CDKN2A mutations has been detected with
discordant frequencies (Haluska and Hodi, 1998). Because of the
influence of different ethnic and environmental factors, and of
high variations in family selection criteria, including 9p21 linkage
and the size of the samples studied, the involvement of CDKN2A
germ line mutations in melanoma families in the world is difficult
to evaluate. Overall, the mutation detection rate in the families
studied is approximately 20%. CDKN2A germ line alterations in
familial melanoma are typically point mutations or small deletions
and insertions in the coding region of the gene. Various mutations
have been shown to cosegregate with melanoma risk in large
pedigrees and to compromise the inhibitory function of p16
(Castellano and Parmiani, 1999), thus supporting their causative
role in melanoma predisposition and tumorigenesis. However, as
indicated by the divergent values of mutation frequencies, many
families do not carry abnormalities in the coding region of the
gene. Activating mutations of the CDK4 gene are rare in the devel-
opment of familial (Zuo et al, 1996; Soufir et al, 1998) or sporadic
melanoma (Wolfel et al, 1995; Guldberg et al, 1997). To date, only
2–6% of all analysed melanoma families have been found to carry
amino acid substitutions, specifically the replacement of arginine
24 with either cysteine or histidine (Wolfel et al, 1995; Brotherton
et al, 1998). Another missense mutation in the p16-binding region
(K22Q) has been demonstrated in a cell line derived from a
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Summary Physical interaction between CDKN2A/p16 and CDK4 proteins regulates the cell cycle progression through the G1 phase and
dysfunction of these proteins by gene mutation is implicated in genetic predisposition to melanoma. We analysed 15 Italian melanoma families
for germ line mutations in the coding region of the CDKN2A gene and exon 2 of the CDK4 gene. One novel disease-associated mutation (P48T),
3 known pathological mutations (R24P, G101W and N71S) and 2 common polymorphisms (A148T and Nt500 G>C) were identified in the
CDKN2A gene. In a family harbouring the R24P mutation, an intronic variant (IVS1, +37 G>C) of uncertain significance was detected in a non-
carrier melanoma case. The overall incidence of CDKN2A mutations was 33.3%, but this percentage was higher in families with 3 or more
melanoma cases (50%) than in those with only 2 affected relatives (25%). Noteworthy, functional analysis established that the novel mutated
protein, while being impaired in cell growth and inhibition assays, retains some in vitro binding to CDK4/6. No variant in the p16-binding region of
CDK4 was identified in our families. Our results, obtained in a heterogeneous group of families, support the view that inactivating mutations of
CDKN2A contribute to melanoma susceptibility more than activating mutations of CDK4 and that other genetic factors must be responsible for
melanoma clustering in a high proportion of families. In addition, they indicate the need for a combination of functional assays to determine the
pathogenetic nature of new CDKN2A mutations. © 2001 Cancer Research Campaign http://www.bjcancer.com
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sporadic melanoma (Tsao et al, 1998). Disruption of either codon
24 or codon 22 is likely to abrogate the interaction between CDK4
and p16 (Coleman et al, 1997; Brotherton et al, 1998). 
To further elucidate the respective contributions of CDKN2A
and CDK4 in familial clustering of melanoma, we performed a
mutational analysis of these genes in 15 Italian melanoma fami-
lies. One novel and 3 already known CDKN2A mutations were
identified mainly in families with multiple melanoma cases with
an overall mutation detection rate of 33.3%. The protein expressed
from the novel mutant allele was found to be normal in in vitro
CDK4- and CDK6-binding activity, but defective in cell growth
and cell-cycle inhibition. Mutations in the p16-binding region of
CDK4 were not detected in our families. 
MATERIALS AND METHODS 
Patients and family collection 
14 melanoma patients with positive family history for the same
malignancy and 1 patient with multiple primary melanomas were
enrolled in the study. All patients were examined and treated at the
National Cancer Institute of Milan. Patients and family members
were invited to participate in this study based on research
purposes. After informed consent, peripheral blood for mutation
analysis was obtained from the proband in 9 families and from the
proband and a second affected member in another 6 families. In
the 5 families in which a CDKN2A mutation was found a total of
48 additional members were identified and sampled for analysis.
All families were of Caucasian origin and living in Italy. Clinical
information including histology, tumour site, age at diagnosis of
melanoma was sought from medical records for all probands and
affected relatives. 
Single strand conformation polymorphism (SSCP)
analysis and DNA sequencing 
For all probands, genomic DNA was extracted by phenol-chloro-
form from lymphoblastoid cell lines established by EBV immor-
talization of peripheral blood lymphocytes as described by Delia
et al (1997). For other available family members, DNA was
extracted from peripheral blood lymphocytes using the QIAamp
Blood Kit (Qiagen). Polymerase chain reaction (PCR) products of
exons 1–3 of CDKN2A gene were screened for mutations by SSCP
analysis, as reported by Donghi et al (1993). SSCP analysis of
CDK4 gene was performed on exon 2 in all probands and in a
second affected member additional to 6 probands, and on exons
2–8 in 4 probands. For CDKN2A, all exons, whether or not they
showed a bandshift, were amplified by a new PCR from genomic
DNA and analysed by direct automated (ABI PRISM Dye
Terminator Cycle Sequencing kit, Perkin Elmer-La Roche) or
manual (Amplitaq Cycle Sequencing Kit, Perkin-Elmer-La
Roche) DNA sequencing. For CDK4, PCR products of exon 2
from all probands were screened for the R24C mutation by Stul
restriction digestion, as well as SSCP, as described by Zuo et al
(1996). 
Functional assays 
The protein–protein interaction assay was performed as previously
described (Parry and Peters, 1996) using radiolabelled compo-
nents translated in vitro from plasmid DNAs. The wild-type or
P48T mutant CDKN2A cDNA was cloned in the pRSET vector, to
facilitate in vitro translation of His6-tagged protein, and CDKs
cDNAs in pBS-KS vector. The CDKN2A cDNA was also inserted
into the pBABEpuro retrovirus vector (Morgenstern and Land,
1990) to allow infection of primary fibroblasts. Two copies of the
HA tag were incorporated at the amino terminus of the wild-type
p16 construct in pBABEpuro. Retroviral infection of TIG-ER
fibroblasts and analysis of cell proliferation effects were
performed according to the previously described procedure (Ruas
et al, 1999). For cell cycle inhibition assay, the CDKN2A cDNA
was cloned into the BamHI site of pCMVneoBam expression
vector (Baker et al, 1990), and transfected in human osteosarcoma
cell line U2OS, negative for p16 expression, together with a
plasmid encoding the CD20 cell surface marker (Koh et al, 1995).
The p16 expression in cotransfected cells was evaluated by
Western blotting and enhanced chemiluminescence detection, as
previously described (Delia et al, 1997). 
RESULTS 
Characterization of the families 
The clinical characteristics of the 15 families screened are summa-
rized in Table 1, and Figure 1A, B shows the distribution of
melanoma-affected relatives in the 5 pedigrees (2587, 2588, 2564,
2624, 2835) carrying CDKN2A germ line mutations. 
The number of melanoma-affected relatives per family ranged
from 1–9. In 6 families at least 3 relatives had melanoma, in 7
other families 2 first-degree relatives were affected, and 1 family
presented with 2 second-degree melanoma relatives and 1 case of
pancreatic cancer. In the remaining case, the proband developed 5
subsequent primary melanomas although his family history was
negative. 4 of the 6 families with 3 or more melanoma cases
included at least one member with multiple primary melanomas.
The age at diagnosis of melanoma in the 15 probands ranged from
25 to 49 years and in 13 families at least one melanoma relative
was diagnosed before age 50. In 5 families, 4 melanoma patients
had an additional diagnosis of colon cancer, lip cancer or basal
cell carcinoma and one additional melanoma proband also 
had multiple basal cell carcinomas. Among the non-penetrant
CDKN2A mutation carriers belonging to families 2587 and 2588, 3
had a diagnosis of Hodgkin disease, oral squamous cell carcinoma
and prostate cancer, respectively. Tumours other than melanoma
and pancreatic cancer occurred in one or more members of a total
of 7 families and they were heterogeneous for type and location. 
Mutational analysis 
Probands from 15 melanoma families were initially screened for
germ line mutations by SSCP analysis of the entire coding
sequence of CDKN2A gene. A total of 6 distinct abnormally
migrating bands were recognized among the amplified exons from
9 probands. By nucleotide sequence analysis, a variant band of
exon 1 was found to be a novel codon 48 mutation. At the position
1 of the codon 48 there was a C to A transversion resulting in the
substitution of proline (CCG) with threonine (ACG) (Figure 2A).
The proband carrying the P48T is a woman of the family 2587
(III:15, Figure 1A) who developed 4 primary melanomas before
age 56. For the other 3 variants, the nucleotide changes were a G to
C transversion at codon 24 (R24P), an A to G transition at codon
71 (N71S), and a G to T transversion at codon 101 (G101W).
BJOC 01-1991 836-844  10/9/01  1:54 pm  Page 837838 G Della Torre et al
British Journal of Cancer (2001) 85(6), 836–844 © 2001 Cancer Research Campaign
33
WT
32
Mut
WT
IVS
25
Mut
24
WT
32
Mut
1
1
1
1
1
1
1
OC
2
OC
3
OC
5
OC
6
OC
7
13 12 11 10 9 8 7 6 5 34
2
2 1
Mut
4
2
2 3 4567 8 9 10 11 12 13 14 15 16
2 3 6 7 8 9 10 4 5
2
23 4 5
11
19 18 17 20 21
12 13
14
22 23 24 25 27 28 30 29 26
15 16 5
7 6
123 45
1
1
2
2
23 2 2 34
5 3 22 2
34 5
67
67 8
Mut
91 0 1 11 21 31 41 51 61 71 81 92 0 2 12 2 2 3 2 4
2 2
89 1 0
MM
55
MM 54
38
73
57
80
24 26 24 12 27 16
77
54
WT
56
WT
59
WT
61
WT
11 12 14 15 16
Mut Mut
Mut Mut Mut Mut Mut
17
Mut Mut
18 19 13
I
II
III
IV
v
I
II
III
IV
I
2564
CDKN2A G101W
2588
CDKN2A R24P
II
III
2
OC
OC OC OC
12 3 4 5 6
OC
OC
MM MM 40
MM 38
84
MM 57 OthCa
Bone npl
85
prostate
54
Mut
52
MM 39
47
MM 43
61
WT
55
MM 31
53
Mut
23
WT
29
Mut
24
WT
28
WT
28
Mut
28
Mut
57
MM 43
55
Mut
OC
3
41
WT
17
WT
19
WT
47
OthCa
HD 30
61
in situ M
47
36
WT
23
Mut
WT
IVS
44
WT
32
WT
31
WT
29
Mut
24
WT
24
Mut
44
MM 41
50
OthCa
Oral Ca.
50
43
MM,
Colon Ca.
(37,41)
57
multiple
MM (39,
39,41,55)
63
multiple
MM, prostate 
(33,39,41,46,58)
60
Lip
tumor,
MM (30,56)
53
multiple
MM 
(38-38-50)
2587
CDKN2A P48T
69
OthCa
Bladder
48
MM 35
40
MM 27
21
Mut
38
Mut
39
Mut Mut Mut
38
MM 36
MM
OthCa
WT
WT
Prostate
Lip tumor, MM
in situ M
MM
Mut
multiple MM
multiple MM, prostate
Mut
WT
MM
OthCa
multiple MM
MM,Colon Ca
Mut
MM
MM MM WT
 
BJOC 01-1991 836-844  10/9/01  1:54 pm  Page 838CDKN2A mutations in Italian melanoma families 839
British Journal of Cancer (2001) 85(6), 836–844 © 2001 Cancer Research Campaign
These changes were detected in 5 of our probands (Table 1) and
represent previously characterized mutations in melanoma fami-
lies. The proband with the R24P mutation of family 2588 (III:14,
Figure 1A) developed 5 primary melanomas (between ages 33 and
58) and later a prostate cancer. The last 2 SSCP variants were
polymorphisms unrelated to melanoma risk. The G to A substitu-
tion at codon 148 of exon 2 (A148T) and the G to C substitution at
Nt500 of the 3′ untranslated region (UTR) within exon 3 were
detected in 2 and 6 melanoma patients, respectively, belonging to
families having 1 or 2 affected relatives (Table 1). Direct DNA
sequencing failed to reveal mutational changes in the 6 probands
with normal SSCP migration patterns for all 3 exons investigated.
In the families of 3 probands, the absence of detectable CDKN2A
mutations was additionally confirmed on a second affected family
member by SSCP analysis and direct sequencing. 
Among the 3 families with extended pedigrees carrying the
P48T, R24P or G101W mutations, 49 family members, including
probands, were available for segregation analysis. In family 2587
(Figure 1A), direct DNA sequencing of exon 1 revealed that the
P48T mutation was carried by 3/3 melanoma patients and 5/18
unaffected family members. Among the 3 affected mutation
carriers one (III:18) developed a melanoma at age 41 diagnosed
during the follow-up programme, and among the 5 unaffected
mutation carriers one (IV:8) had Hodgkin disease when she was 30
years old, and another one (III:17) was diagnosed during follow-
up, at age 50, with a well differentiated squamous cell carcinoma
of the soft palate. The 5 non-penetrant carriers of the mutation
ranged in age from 23 to 50 years. Out of 12 mutation carriers
including obligate ones, 6 (50%) had developed melanoma.
Among the 21 available members of family 2588 (Figure 1A), the
R24P mutation was identified in 5/6 affected and 9/15 unaffected
individuals. The age of the 9 non-penetrant carriers ranged from
25 to 55 years. Of 17 carriers and obligate carriers of the mutation,
6 (35%) had melanoma. The affected member (III:10) who did not
carry the expected mutation showed heterozygosity for the poly-
morphism at Nt500 of the 3′ UTR and the presence of a G to C
change at nucleotide +37 of intron 1 (based on GenBank accession
number U12818) of unknown biological significance (Figure 2B).
Both changes were also detected in his unaffected daughter
(IV:17). The 3′ UTR polymorphism did not segregate with
melanoma and the intron 1 variant was not encountered in any of
the other 19 available family members. We have not yet been able
to establish if the intron 1 variant was inherited from the paternal
or the maternal lineage. Potential effects of this variant on the
splicing of the gene were investigated by using the Splice View
program (http://125.itba.mi.cnr.It/genebin/wwwspliceview), and
no defect in RNA processing was predicted. In family 2564
(Figure 1A), the presence of the G101W mutation was investi-
gated in 7 family members and it was identified in one case of
melanoma (proband), 2/2 cases of dysplastic nevi (III:3; III:7) and
3/4 unaffected individuals. 4 affected siblings of the second gener-
ation were deceased before the beginning of the study but they
represented obligate carriers. In family 2624 (Figure 1B), the
N71S substitution was not identified in the unaffected son of the
proband. The segregation of this variant with melanoma could not
be studied, as other family members were not available for testing.
In family 2835 (Figure 1B), the G101W substitution was also
identified in the mother of the proband, the only available affected
member of the family. 
Proband and a second affected member of 5 mutation-negative
families (2629, 2603, 2589, 2626, 2586) were also tested for muta-
tions in 1200 bp of the promoter region upstream of the CDKN2A
start codon, in the laboratory of the Center for Hereditary Tumor 
in Genoa by Mantelli et al (personal communication). The 
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Table 1 Clinical and molecular characteristics of 15 Italian families 
Family  No of No of melanoma patient Age (years) at diagnosis Other tumours developed by Other tumours developed CDKN2A genec CDK4
members  melanoma with multiple primary of melanoma melanoma patients or CDKN2A by family members Coding Nt 500 gene WT
ID patient/familyd melanomas mutation carriers region 3′ UTR in exon:
2587 9 1 39b–60 colon cancer, Hodgkin disease,  ‘bone’ tumour P48T C/C 2 to 8 
oral squamous cell carcinoma
2588 8a 23 1 –56 prostate cancer, ‘lip’ tumour – R24P C/C 2 to 8 
2564 6 – 27b–42 – bladder cancer G101W C/C 2 to 8 
2565-A 6a – 37–62 – uterus cancer wt C/C 2 to 8 
2565-B wt C/C 2 
2623 3 2 33b–35 – uterus cancer wt C/C 2 
2629-A 3 1a 49b–UNK multiple basal cell carcinomas – wt C/C 2 
2629-B wt C/C 2 
2603 2a(1st) – 21–36b –– wt C/C 2 
2589-A 2(1st) – 31b–UNK basal cell carcinoma – wt C/C 2 
2589-B wt C/C 2 
2624 2(1st) – <30–32b – oesophagus and uterus cancer N71S C/C 2 
2626-A 2(1st) – 38b–48 – colon, stomach and A148T C/G 2 
2626-B ovarian cancer A148T C/G 2 
2586-A 2(1st) – 42b–43 –– wt C/G 2 
2586-B wt C/G 2 
2764 2(1st) – 43–49b basal cell carcinoma multiple mieloma wt C/G 2 
2835-A 2(1st) – 25b–63 –– G101W C/C 2 
2835-B G101W C/C 2 
2762 2(2nd) – 49b–>75 – pancreatic cancer wt C/C 2 
2577 1 1 (5 primary tumours) 37b –– wt C/G 2 
aIn situ melanoma (pre-malignant melanosis) included; bindex case; cPolymorphisms are shown in italics; dthe degree of relatedness is indicated in parentheses; UNKUnknown age at diagnosis. 
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functionally deleterious –34 G > T promoter variant, the only one
known to segregate with melanoma risk (Harland et al, 2000), was
not detected in any of these families. 
In screening the CDK4 gene, the previously described exon 2
R24C mutation was not detected by StuI restriction digestion in
any of the 15 probands analysed. SSCP analysis revealed no
abnormal migration patterns either in exon 2 (all 15 probands
analysed) or the 6 additional coding exons (4 probands analysed),
thus excluding that, at least for exon 2, mutations other than those
at critical residues 24 and 22 may functionally protect CDK4
protein from p16 inhibition. 
Functional analysis of the P48T mutant protein 
The p16 protein carrying the novel P48T missense mutation was
initially tested for its ability to interact with specific CDKs in a direct
in vitro binding assay. The mixed proteins were immunoprecipitated
with an antiserum against p16 and analysed by SDS-PAGE. As
revealed in Figure 3A, the P48T variant was indistinguishable from
wild-type p16 in its ability to interact with CDK4 or CDK6, while the
previously documented mutant A20P (Ruas et al, 1999) showed no
detectable binding to CDK4 or CDK6. Neither the wild-type nor the
variant p16 proteins interacted with CDK2 (data not shown).
In vitro binding to CDK4/6 represents a relatively simple but
non-quantitative test of p16 function and previous investigations
have revealed a number of cancer-associated p16 variants that
retain CDK-binding potential in vitro yet appear functionally
impaired in vivo (Ruas et al, 1999). To determine whether the
P48T variant belonged to this category, we used a recombinant
retrovirus to express this variant in human diploid fibroblasts
engineered to express the receptor for ecotropic viruses (TIG-ER
cells) (Ruas et al, 1999). By monitoring the proliferation of
TIG-ER cells expressing the P48T variant (Figure 3B), we
found that this mutant protein had a diminished ability to inhibit
cell growth, whereas wild-type p16 caused growth arrest and the
empty vector had no effect on cell proliferation. 
We additionally assess the function of the P48T variant by an
alternative assay based on the ectopic expression of p16 in U2OS
cells. These cells were transiently transfected with expression
plasmid carrying the P48T mutated allele and analysed by flow
cytometry for cell cycle phase redistribution. The DNA
histograms (Figure 3C) show that overexpression of wild-type
protein led to a specific accumulation of cells in G1 (75.5% versus
45% for control transfectants), as expected. Conversely, over-
expression of the mutated p16 protein caused a reduction of G1
phase cells (61%), consistent with a defect in the arrest at the G1/S
boundary. The appropriate expression levels of wild-type and
mutated p16 protein in transfected cells were verified by protein
immunoblotting (Figure 3C). 
DISCUSSION 
Mutation analysis of the CDKN2A gene in 15 Italian families has
revealed a novel germ line variant, the P48T that clearly segre-
gates with melanoma in family 2587, and the missense mutations
R24P, G101W (two families) and N71S already known to be
disease-associated. The P48T is located in the first ankyrin repeat
at a non-conserved amino acid inside the NH2-terminus (AA 9–72)
of the protein. As revealed by deletion studies on p16 (Lilischkis
et al, 1996), this region is important for the inhibitory activity of
p16 like the central domain (AA 73–131), where inactivating
missense mutations usually reside. We found that the P48T variant
of p16 is functionally impaired in its ability to inhibit the cell
growth and cell cycle progression, thus suggesting a causal role for
this mutation. However, the in vitro CDK binding assay has shown
that the P48T variant retains some activity, placing it in the cate-
gory of mutants that are partially impaired (Ruas et al, 1999).
Interestingly, the P48 residue has been shown to be structurally
buried, contributing to the hydrophobic core of the protein, and
previous analysis of a different alteration at this residue, P48L,
revealed a p16 variant defective in both CDK binding in vitro and
cell proliferation inhibition (Ruas et al, 1999). Thus, different
alterations of codon 48 have slightly different effects on the 
function of the protein. The R24P mutation has been reported in
one Australian (Holland et al, 1995), one English (Harland et al,
1997) and two French (Soufir et al, 1998) melanoma-prone fami-
lies. The G101W is a disease-related mutation quite common in
melanoma-prone families of European origin (Ghiorzo et al,
A P48T IVSI + 37G→  C B
C G G A G G M C G ATC C GATGGCSGGCGA
Figure 2 CDKN2A gene sequence analysis. (A) The novel P48T germ line mutation found in the family 2587. (B) Identification of an Intronic Variant Sequence
in intron 1 (+37 G > C) in a phenocopy (III:10) of the family 2588 carrying the disease-associated R24P mutation. Arrows indicate nucleotide changes 
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1999). Differently, the N71S is only weakly correlated with
melanoma risk and regarded by some authors as rare polymor-
phism, even if absent in normal controls (Ranade et al, 1995).
These three variants have all been functionally tested and shown to
be partially defective. Notably, the R24P displayed binding
activity to CDK6, but not to CDK4 (Harland et al, 1997), and the
G101W temperature sensitivity in binding to CDK4 and CDK6 in
vitro and in the kinase inhibition and cell cycle arrest assays (Parry
and Peters, 1996). The N71S, alike to P48T, retained CDK-
binding activity but behaved as partially impaired in the cell
proliferation assay (Ruas et al, 1999). 
Italian melanoma families commonly have a small number of
affected relatives and the likelihood that these families represent
clustering of sporadic cases is minor because of the low melanoma
incidence in the Italian population (Ghiorzo et al, 1999). In our
series of 15 Italian melanoma families, 25% of families with 2
affected relatives and 50% of families with 3 or more affected rela-
tives had identifiable melanoma specific CDKN2A mutations. The
small sample size of our study may have contributed to these high
mutation rates. In other studies on larger clinical populations
(Holland et al, 1999; Ruiz et al, 1999; Borg et al, 2000; Goldstein
et al, 2000) lower prevalences of mutations have been reported.
However, the difference we found in the probability of identifying
CDKN2A mutations in families of different size is consistent with
that reported worldwide and it appears to be dependent on the
strength of family history (Soufir et al, 1998). In a recent collabo-
rative study with Mantelli et al (personal communication) on 62
Italian families CDKN2A mutations have been found to be signifi-
cantly more likely in small families when one of the 2 affected
members carries multiple primary melanomas or when pancreatic
cancer is present in additional family members. This finding can
account for the absence of mutations found in most of our families
with 2 affected members, as these were free of clinical features
predictive of mutation. Additionally, it might imply that some 2-
case families of our subset are more likely to represent clustering
of sporadic melanomas, or that they carry less penetrant mutant
genes. Of note, 2 of the latter families and one family with 3
melanoma cases were characterized by melanoma patients also
affected by basal cell carcinoma, thus suggesting a different
disease phenotype. 
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melanoma one individual diagnosed with melanoma had no
detectable mutated allele at codon 24 in 2 different blood samples,
although the age at diagnosis was consistent with that of the other
affected relatives. We believe that this individual may be a case of
sporadic melanoma (phenocopy), as the segregation of the muta-
tion in 5/6 affected relatives seems unlikely to be a coincidence.
Alternatively, co-segregation of another genetic factor cooperating
with the CDKN2A gene in the predisposition to melanoma could
account for the presence of a non-carrier melanoma case and the
penetrance of the mutation in this family. The intron 1 variant
carried by this individual has not, to our knowledge, been reported
before. As this variant, which is not predicted to be critical for
protein expression, was not encountered in the other affected or
unaffected relatives, we presume that it is a silent variant,
possibly of maternal origin, with no role in the development of
melanoma. 
In our families, evidence for the presence of tumours additional
to melanoma indicates a high heterogeneity, as already observed in
melanoma families of various geographical origins (Ghiorzo et al,
1999). In studies aimed at investigating whether familial suscepti-
bility to melanoma increases the risk of other tumours, increased
risks of pancreatic and breast carcinomas have been found in
CDKN2A mutation carriers (Goldstein et al, 1995; Borg et al,
2000). Other studies suggest that germ line CDKN2A-impairing
function mutations may also predispose to head and neck squa-
mous cell carcinomas in familial melanoma (Yarbrough et al,
1996). The observed number of non-melanoma tumours in our
families is too small for a risk analysis. A single case of pancreatic
carcinoma was present in our series of families and it occurred in a
member of a CDKN2A mutation-negative family. Of clinical rele-
vance could be the observation of one P48T mutation carrier from
the family 2587 who developed an oral squamous cell carcinoma
during the follow-up. 
The absence of any CDK4 mutations in our families supports
the conclusion that the activation of this gene is infrequent in
familial melanoma and that in this cancer syndrome the deregula-
tion of the RB pathway occurs mainly through mutations in
CDKN2A. However, we found no CDKN2A germ line mutations in
a large proportion of families with either 2 or more affected rela-
tives. It is still open to investigation that mutations outside the
coding region that result in dysregulation of gene expression might
be a possible cause of melanoma predisposition. To date, mutation
screening of the CDKN2A promoter region in familial melanoma
has revealed that causal mutations at this site are rarely present in
families with no detectable coding mutations (Harland et al, 2000;
Mantelli et al, personal communication). 
In conclusion, we confirm in this study the significant role of
CDKN2A mutations in melanoma-prone families having 3 or more
affected relatives. Furthermore, functional data point out that
CDKN2A mutations may require complementary functional assays
to establish their pathogenetic role. 
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